Serum concentrations of antidepressant drugs in a naturalistic setting: Compilation based on a large therapeutic drug monitoring database

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 42-56

  Reis, Margareta ^a,c   Aamo, Trond ^b   Spigset, Olav ^b   Ahlner, Johan ^a  

^a Swedish National Board of Forensic Medicine   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressant drugs; Serotonin noradrenaline reuptake inhibitor; SSRI; TCA; TDM

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESMETHYLMIRTAZAPINE; DRUG METABOLITE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORCITALOPRAM; NORCLOMIPRAMINE; NORFLUOXETINE; NORMIANSERIN; NORSERTRALINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRIMIPRAMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOTRANSFORMATION; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; NORWAY; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; YOUNG ADULT;

EID: 60449119332     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819114ea     Document Type: Article

References (64)

1. Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drag therapy. Br Med J. 1969;4:764-768.
2. Mellström B, Bertilsson L, Traskman L, et al. Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology. 1979;19:282-287.
3. Åsberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971;3:331-334.
4. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;3I: 444-469.
5. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
6. Balant-Gorgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14:612-614; discussion 611.
7. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(Suppl): 14-34; discussion 55-16.
8. Rasmussen BB, Brasen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154.
9. Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004;26:167-170.
10. Preskorn SH. Tricyclic antidepressants: the whys and hows of therapeutic drag monitoring. J Clin Psychiatry. 1989;50(Suppl):34-42; discussion 43-36.
11. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37:147-165.
12. Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drag monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354-359.
13. Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drags. Pharmacopsychiatry. 2006;39:121-127.
14. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA task force report. Task force on the use of laboratory tests in psychiatry. Am J Psychiatry. 1985;142:155-162.
15. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drag monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
16. Hiemke C. Clinical utility of drag measurement and pharmacokinetics - therapeutic drag monitoring in psychiatry. Eur J Clin Pharmacol. 2008;64:159-166.
17. Lundmark J, Reis M, Bengtsson F. Therapeutic drag monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
18. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit. 2001;23:139-147.
19. Reis M, Lundmark J, Björk H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-553.
20. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191.
21. Reis M, Åberg-Wistedt A, Ågren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol. 2004;19:283-291.
22. Reis M, Prochazka J, Sitsen A, et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit. 2005;27:469-477.
23. Reis M, Åberg-Wistedt A, Ågren H, et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disord. 2004;82:443-446.
24. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005;28:565-581.
25. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(Suppl):54-59.
26. Reis M, Aamo T, Ahlner J, et al. Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J Anal Toxicol. 2007;31:254-264.
27. Vandel S, Bertschy G, Vandel B, et al. Amitriptyline: linear or nonlinear kinetics in every day practice? Eur J Clin Pharmacol. 1989; 37:595-598.
28. Fredricson Overø K. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6: 311-318.
29. Kuss HJ, Jungkunz G. Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:739-748.
30. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17:343-362.
31. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45:1400-1406.
32. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26:201-214.
33. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1994;27:175-190.
34. Spigset O, Granberg K, Hagg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998;45:257-263.
35. Shami M, Elliott HL, Kelman AW, et al. The pharmacokinetics of mianserin. Br J Clin Pharmacol. 1983;15:313S-322S.
36. Otani K, Sasa H, Kaneko S, et al. Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin. Ther Drug Monit. 1993;15:113-117.
37. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461-474.
38. Schoerlin MP, Mayersohn M, Korn A, et al. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther. 1987;42: 395-404.
39. Jerling M, Alvan G. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring. Eur J Clin Pharmacol. 1994;46:67-70.
40. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl. 1989;350:60-75.
41. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000;39:413-427.
42. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32(Suppl 1):22-30.
43. Musa MN. Nonlinear kinetics of trimipramine in depressed patients. J Clin Pharmacol. 1989;29:746-747.
44. Kirchheiner J, Sasse J, Meineke I, et al. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics. 2003;13:721-728.
45. Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active 0-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724.
46. Snedecor GW, Cochran, William G. Statistical Methods. 7th ed. Ames, IA: Iowa State University Press; 1980.
47. Reis M, Cherma MD, Carlsson B, et al. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007;29: 758-766.
48. Bengtsson F. Therapeutic drag monitoring of psychotropic drugs. TDM "nouveau." Ther Drug Monit. 2004;26:145-151.
49. Öhman D, Cherma MD, Norlander B, et al. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit. 2003;25:174-182.
50. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther. 1999;66:152-165.
51. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;2:584-586.
52. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979;16:183-187.
53. Bertilsson L, Dahl M-L. Polymorphic drag oxidation, relevance to the treatment of psychiatric disorders. CNS Drugs. 1996;5:200-223.
54. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys. 1993;306: 240-245.
55. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry. 1994;33:1743-1752.
56. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
57. Bresen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001;11:275-283.
58. Plant N. The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta. 2007;1770:478-488.
59. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007; 29:687-710.
60. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310-322.
61. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med. 1993;94:2S-12S.
62. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61: 331-339.
63. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329-342.
64. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001;21:500-515.